Files
Download Full Text (10.4 MB)
Contents
- Molecular research leads to clinical trials for bladder cancer
- Patients to test exercise theory in quality-of-life study
- Practice guidelines and collaborative paths point the way
- Protocols: Bladder Cancer Clinical Trials Interventions Span Surgery, Chemotherapy, Radiotherapy, and Genetic Manipulation
- DiaLog: The New Math of Today’s Health Care, by Mitchell Morris, MD, Vice President for Information and Health Care Systems
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
Publication Date
4-1998
Publisher
The University of Texas MD Anderson Cancer Center
City
Houston, Texas
Keywords
Grossman, Barton; Dinney, Colin; Eve, Beryl; Benedict, William; Pagliaro, Lance; Radinsky, Robert; Millikan, Randall; Morris, Mitchell; Murphy, Loretta; Gritz, Ellen R.; Levin, Bernard, 1942-; Carmack, Cindy; Urinary Bladder Neoplasms; Clinical Trials as Topic; Tumor Suppressor Protein p53; Genes, Retinoblastoma; Retinoblastoma Protein; Doxorubicin -- analogs & derivatives; Mycobacterium bovis; Precision Medicine; Urinary Bladder Neoplasms -- secondary; Urothelium; Chemoprevention; Fenretinide; ErbB Receptors; Cetuximab; Antineoplastic Agents; Practice Guidelines as Topic; Prostatic Neoplasms; Exercise; Healthy Lifestyle; Quality of Life; Surveys and Questionnaires.
Disciplines
History of Science, Technology, and Medicine | Oncology
Recommended Citation
Patterson, Sunita; Hosemann, Sunni; Ruffin, Alison; and Morris, Mitchell MD, "OncoLog, Volume 43, Number 04, April 1998" (1998). OncoLog MD Anderson's Report to Physicians (All issues). 61.
https://openworks.mdanderson.org/oncolog/61
Conditions Governing Access
Redacted
